Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,295.08 +17.57 (+0.33%) Dow
38,662.80 -23.52 (-0.06%) Nasdaq
16,865.90 +130.89 (+0.78%) Bitcoin USD
69,908.59 +1,805.43 (+2.65%) CMC Crypto 200
1,503.79 +35.85 (+2.44%)
IRWD Dec 2024 10.000 put
| Previous close | 3.5900 |
| Open | 3.6400 |
| Bid | 1.1000 |
| Ask | 5.4000 |
| Strike | 10.00 |
| Expiry date | 2024-12-20 |
| Day's range | 3.5900 - 3.6400 |
| Contract range | N/A |
| Volume | |
| Open interest | 31 |
Business WireIronwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City.
Business WireIronwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
BOSTON, May 21, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present late-breaking data during the 2024 Digestive Disease Week® (DDW) meeting from its pivotal Phase III clinical trial, STARS, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in adult patients with short bowel syndrome with intestinal failure (SBS-IF). These findings build on the positive topline data that Ironwood previously announced in February 2024. B
Simply Wall St.US$16.33: That's What Analysts Think Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Is Worth After Its Latest Results
It's been a sad week for Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ), who've watched their investment drop 14% to...
